IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved]
Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2025-01-01
|
| Series: | Open Research Europe |
| Subjects: | |
| Online Access: | https://open-research-europe.ec.europa.eu/articles/4-119/v2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540451920412672 |
|---|---|
| author | Tamara Saksida Alessia di Flora Marina Romero-Ramos Vladimirs Pilipenko Laura Muñoz Delgado Franca Marino Yasemin Gursoy Ozdemir Neda Nikolovski Cristoforo Comi Dale Lawson Inês Figueira Mitilda Gugu Simona Poletti Shubhra Acharya Dogukan Pira |
| author_facet | Tamara Saksida Alessia di Flora Marina Romero-Ramos Vladimirs Pilipenko Laura Muñoz Delgado Franca Marino Yasemin Gursoy Ozdemir Neda Nikolovski Cristoforo Comi Dale Lawson Inês Figueira Mitilda Gugu Simona Poletti Shubhra Acharya Dogukan Pira |
| author_sort | Tamara Saksida |
| collection | DOAJ |
| description | Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. |
| format | Article |
| id | doaj-art-458790baa9b44bf690ff5b80590446d3 |
| institution | Kabale University |
| issn | 2732-5121 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | Open Research Europe |
| spelling | doaj-art-458790baa9b44bf690ff5b80590446d32025-02-05T01:00:00ZengF1000 Research LtdOpen Research Europe2732-51212025-01-01420833IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved]Tamara Saksida0https://orcid.org/0000-0002-2527-3246Alessia di Flora1https://orcid.org/0000-0003-4199-4307Marina Romero-Ramos2Vladimirs Pilipenko3https://orcid.org/0000-0002-7098-7483Laura Muñoz Delgado4Franca Marino5Yasemin Gursoy Ozdemir6Neda Nikolovski7Cristoforo Comi8Dale Lawson9https://orcid.org/0009-0003-7837-1311Inês Figueira10https://orcid.org/0000-0002-0860-8964Mitilda Gugu11https://orcid.org/0000-0002-5064-3915Simona Poletti12Shubhra Acharya13https://orcid.org/0000-0003-2904-6566Dogukan Pira14Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, SerbiaCenter for Research in Medical Pharmacology, School of Medicine, University of Insubria, Varese, Lombardy, ItalyDanish Research Institute of Translational Neuroscience – DANDRITE & Department of Biomedicine, Aarhus University, Aarhus, Central Denmark Region, DenmarkDepartment of Pharmacology, Faculty of Medicine, University of Latvia, Riga, Riga, LatviaUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Seville, Andalusia, SpainCenter for Research in Medical Pharmacology, School of Medicine, University of Insubria, Varese, Lombardy, ItalyDepartment of Neurology, School of Medicine, Koç University, Istanbul, İstanbul, TurkeyInstitute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, SerbiaDepartment of Translational Medicine, University of Eastern Piedmont, Novara, ItalyUniversity of Eastern Piedmont, Novara, ItalyNOVA Medica School | Faculdade de Ciências Médicas (NMS|FCM), Universidade Nova de Lisboa, Lisbon, Lisbon, PortugalPreclinical Department, Faculty of Technical Medical Sciences, University of Elbasan “Aleksandër Xhuvani”, Elbasan, AlbaniaDepartment of Translational Medicine, University of Eastern Piedmont, Novara, ItalyLuxembourg and Faculty of Science, Technology and Medicine, University of Luxembourg, Luxembourg, LuxembourgFaculty of Medicine, Izmir University of Economics, Izmir, TurkeyParkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD.https://open-research-europe.ec.europa.eu/articles/4-119/v2Parkinson's disease immune response networkeng |
| spellingShingle | Tamara Saksida Alessia di Flora Marina Romero-Ramos Vladimirs Pilipenko Laura Muñoz Delgado Franca Marino Yasemin Gursoy Ozdemir Neda Nikolovski Cristoforo Comi Dale Lawson Inês Figueira Mitilda Gugu Simona Poletti Shubhra Acharya Dogukan Pira IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] Open Research Europe Parkinson's disease immune response network eng |
| title | IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] |
| title_full | IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] |
| title_fullStr | IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] |
| title_full_unstemmed | IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] |
| title_short | IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET [version 2; peer review: 2 approved] |
| title_sort | immunity unveiled a translational network for tackling parkinson s disease immuparknet version 2 peer review 2 approved |
| topic | Parkinson's disease immune response network eng |
| url | https://open-research-europe.ec.europa.eu/articles/4-119/v2 |
| work_keys_str_mv | AT tamarasaksida immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT alessiadiflora immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT marinaromeroramos immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT vladimirspilipenko immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT lauramunozdelgado immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT francamarino immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT yasemingursoyozdemir immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT nedanikolovski immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT cristoforocomi immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT dalelawson immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT inesfigueira immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT mitildagugu immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT simonapoletti immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT shubhraacharya immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved AT dogukanpira immunityunveiledatranslationalnetworkfortacklingparkinsonsdiseaseimmuparknetversion2peerreview2approved |